Enliven Historical Income Statement
| ELVN Stock | 25.41 1.06 4.35% |
Historical analysis of Enliven Therapeutics income statement accounts such as Total Operating Expenses of 87.7 M or Total Other Income Expense Net of 12.5 M can show how well Enliven Therapeutics performed in making a profits. Evaluating Enliven Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Enliven Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Enliven Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Enliven Therapeutics is a good buy for the upcoming year.
Enliven |
About Enliven Income Statement Analysis
Enliven Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Enliven Therapeutics shareholders. The income statement also shows Enliven investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Enliven Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Enliven Therapeutics. It is also known as Enliven Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Enliven Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Enliven Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.At this time, Enliven Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 28th of November 2024, Net Interest Income is likely to grow to about 12.6 M, though Operating Income is likely to grow to (79.4 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 22K | 1.1M | 12.0M | 12.6M | Cost Of Revenue | 99K | 622K | 297K | 252.6K |
Enliven Therapeutics income statement Correlations
Click cells to compare fundamentals
Enliven Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Enliven Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Operating Expenses | 24.1M | 9.3M | 24.8M | 38.8M | 83.5M | 87.7M | |
| Operating Income | (24.1M) | (9.3M) | (24.8M) | (38.8M) | (83.5M) | (79.4M) | |
| Research Development | 19.0M | 8.2M | 20.5M | 31.0M | 64.6M | 67.8M | |
| Ebitda | (24.1M) | (9.3M) | (24.6M) | (38.6M) | (81.9M) | (77.8M) | |
| Total Operating Expenses | 24.1M | 9.3M | 24.8M | 38.8M | 83.5M | 87.7M | |
| Income Before Tax | (23.5M) | (19.0M) | (24.7M) | (37.7M) | (71.6M) | (68.0M) | |
| Total Other Income Expense Net | 653K | (9.6M) | 22K | 1.1M | 11.9M | 12.5M | |
| Income Tax Expense | 653K | (31K) | (22K) | 88K | 1.3M | 1.4M | |
| Depreciation And Amortization | 33K | 97K | 115K | 215K | 297K | 311.9K | |
| Selling General Administrative | 5.1M | 1.1M | 4.3M | 7.8M | 19.0M | 19.9M | |
| Ebit | (24.1M) | (9.4M) | (24.8M) | (38.8M) | (82.2M) | (78.1M) | |
| Net Income | (23.5M) | (18.9M) | (24.7M) | (37.8M) | (71.6M) | (68.0M) |
Pair Trading with Enliven Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enliven Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enliven Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Enliven Stock
| 0.83 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.71 | RGNX | Regenxbio | PairCorr |
| 0.67 | INKT | Mink Therapeutics | PairCorr |
| 0.62 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.6 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
The ability to find closely correlated positions to Enliven Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enliven Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enliven Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enliven Therapeutics to buy it.
The correlation of Enliven Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enliven Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enliven Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enliven Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.